Ambiguous roles and potential therapeutic strategies of innate lymphoid cells in different types of tumor.
anti-tumor activity
cancer immunotherapy
heterogeneity
innate lymphoid cells
neoplasms
plasticity
Journal
Oncology letters
ISSN: 1792-1074
Titre abrégé: Oncol Lett
Pays: Greece
ID NLM: 101531236
Informations de publication
Date de publication:
Aug 2020
Aug 2020
Historique:
received:
11
09
2019
accepted:
07
04
2020
entrez:
30
7
2020
pubmed:
30
7
2020
medline:
30
7
2020
Statut:
ppublish
Résumé
Recent years have witnessed a significant development in the current understanding of innate lymphoid cells (ILCs) and their roles in the innate immune system, where they regulate tissue homeostasis, inflammation, as well as tumor surveillance and tumorigenesis. Based on the limited studies of ILCs in cancer, ILCs may be classified into three subgroups depending on their phenotypic and functional characteristics: Group 1 ILCs, which include natural killer cells and ILC1s; Group 2 ILCs, which only contain ILC2s and Group 3 ILCs, which comprise of LTi cells and ILC3s. Group 1 ILCs predominantly exert antitumor activities, while Group 2 ILCs and Group 3 ILCs are predominantly procarcinogenic in nature. In different types of tumor, each ILC subset behaves differently. Current research is focused on investigating how ILCs may be manipulated and employed as therapeutic strategies for the treatment of cancer. The present review aimed to summarize the characteristics and effects of ILCs in the context of tumor immunology, and provide novel insight into the pro- or anti-tumor activities of ILCs in different types of malignancy, including solid tumors, such as those in the gastrointestinal tract, lung, breast, bladder or prostate, as well as melanoma, further to hematological malignancies, with the aim to highlight potential therapeutic targets for the treatment of cancer.
Identifiants
pubmed: 32724393
doi: 10.3892/ol.2020.11736
pii: OL-0-0-11736
pmc: PMC7377136
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1513-1525Informations de copyright
Copyright: © Wang et al.
Références
Nat Immunol. 2010 Nov;11(11):1030-8
pubmed: 20935648
Front Immunol. 2019 Mar 29;10:649
pubmed: 30984202
Adv Immunol. 2010;108:21-44
pubmed: 21056728
Immunity. 2012 Aug 24;37(2):339-50
pubmed: 22921121
Curr Top Microbiol Immunol. 2016;395:115-45
pubmed: 26025472
World J Gastroenterol. 2014 Apr 28;20(16):4586-96
pubmed: 24782611
Clin Cancer Res. 2019 Jul 1;25(13):4026-4037
pubmed: 30979738
Nat Immunol. 2015 Feb;16(2):161-9
pubmed: 25531830
Eur J Immunol. 2017 Aug;47(8):1342-1353
pubmed: 28586167
Nat Med. 2017 Mar;23(3):368-375
pubmed: 28165478
Immunity. 2015 Jul 21;43(1):146-60
pubmed: 26187413
Hum Vaccin Immunother. 2018;14(8):2012-2015
pubmed: 29617184
Science. 2010 May 7;328(5979):749-52
pubmed: 20339029
Nat Immunol. 2016 Jun;17(6):646-55
pubmed: 27111142
Nature. 2010 Apr 29;464(7293):1367-70
pubmed: 20200518
Nat Immunol. 2013 Mar;14(3):221-9
pubmed: 23334791
Nature. 2010 Apr 29;464(7293):1371-5
pubmed: 20393462
Immunology. 2016 Oct;149(2):123-30
pubmed: 27341319
Nat Med. 2008 Mar;14(3):282-9
pubmed: 18264109
Nat Rev Immunol. 2014 Sep;14(9):585-600
pubmed: 25145755
Nature. 2010 Apr 29;464(7293):1362-6
pubmed: 20200520
Nat Rev Immunol. 2013 Feb;13(2):145-9
pubmed: 23348417
J Immunol Res. 2014;2014:923135
pubmed: 24741632
J Clin Invest. 2017 Aug 1;127(8):2916-2929
pubmed: 28650339
Cell. 2018 Aug 23;174(5):1054-1066
pubmed: 30142344
Mol Med Rep. 2017 Jun;15(6):4374-4381
pubmed: 28487978
Science. 2010 Jan 15;327(5963):291-5
pubmed: 20075244
Cancer Immunol Res. 2015 Mar;3(3):296-304
pubmed: 25600438
J Immunol. 2016 Mar 1;196(5):2410-23
pubmed: 26829987
Haematologica. 2015 Jul;100(7):e257-60
pubmed: 25710455
Nat Immunol. 2016 Jun 21;17(7):765-74
pubmed: 27328006
Leukemia. 2018 Sep;32(9):1994-2007
pubmed: 29588546
Nat Immunol. 2016 Jun;17(6):626-35
pubmed: 27111143
Nat Immunol. 2011 Nov;12(11):1045-54
pubmed: 21946417
Immunity. 2010 Nov 24;33(5):752-64
pubmed: 21055975
Int Immunol. 2016 Jan;28(1):43-52
pubmed: 26451009
Front Immunol. 2019 Apr 03;10:656
pubmed: 31024531
Front Immunol. 2019 Jun 04;10:1235
pubmed: 31214189
Cancer Res. 2017 Mar 1;77(5):1083-1096
pubmed: 28082403
J Immunol. 2012 Jan 15;188(2):703-13
pubmed: 22174445
Cytokine Growth Factor Rev. 2014 Jun;25(3):257-71
pubmed: 24856143
Thorax. 2011 Sep;66(9):834-5
pubmed: 21680565
J Clin Invest. 2014 Jul;124(7):3241-51
pubmed: 24892809
Food Sci Nutr. 2019 Feb 10;7(4):1288-1294
pubmed: 31024701
Cell Mol Immunol. 2015 May;12(3):292-302
pubmed: 25308752
Haematologica. 2016 Nov;101(11):e461-e464
pubmed: 27662009
Nat Commun. 2017 Sep 19;8(1):593
pubmed: 28928446
Nat Immunol. 2013 Mar;14(3):281-9
pubmed: 23334788
J Exp Med. 2016 Apr 4;213(4):569-83
pubmed: 26976630
Cancer Immunol Immunother. 2016 Apr;65(4):465-76
pubmed: 26289090
Immunity. 2013 Aug 22;39(2):357-71
pubmed: 23954132
Nat Immunol. 2008 Jun;9(6):667-75
pubmed: 18425132
Int Rev Immunol. 2015;34(6):509-22
pubmed: 25730441
Nat Rev Immunol. 2018 Jan;18(1):62-76
pubmed: 28853443
Annu Rev Immunol. 2016 May 20;34:539-73
pubmed: 26927206
Eur J Immunol. 1975 Feb;5(2):117-21
pubmed: 1086218
Annu Rev Immunol. 2012;30:647-75
pubmed: 22224763
Int J Cancer. 2019 Sep 15;145(6):1660-1668
pubmed: 30856277
Nature. 2010 Jan 28;463(7280):540-4
pubmed: 20023630
Curr Opin Gastroenterol. 2013 Nov;29(6):581-7
pubmed: 24100718
Blood. 2014 Jul 31;124(5):812-21
pubmed: 24855210
J Exp Med. 2011 Jun 6;208(6):1127-33
pubmed: 21576383
Lancet. 2001 Feb 17;357(9255):539-45
pubmed: 11229684
Immunity. 2015 Feb 17;42(2):216-226
pubmed: 25692699
Nat Rev Gastroenterol Hepatol. 2018 Dec;15(12):721-737
pubmed: 30185915
Science. 2015 May 22;348(6237):aaa6566
pubmed: 25999512
Mucosal Immunol. 2014 Jul;7(4):842-56
pubmed: 24280935
Nature. 2009 Feb 5;457(7230):722-5
pubmed: 18978771
J Immunother. 2007 Jan;30(1):16-28
pubmed: 17198080
Sci Signal. 2016 May 03;9(426):ra45
pubmed: 27141929
J Exp Med. 2013 May 6;210(5):917-31
pubmed: 23589566
Immunol Lett. 2014 Jan-Feb;157(1-2):23-37
pubmed: 24231232
Hepatology. 2011 Sep 2;54(3):900-9
pubmed: 21674558
Gut Pathog. 2019 May 15;11:23
pubmed: 31123503
Nat Commun. 2015 Sep 23;6:8280
pubmed: 26395069
Oncoimmunology. 2015 Feb 03;4(1):e984539
pubmed: 25949866
Nat Rev Clin Oncol. 2016 May;13(5):273-90
pubmed: 26977780
Lancet. 2017 Mar 18;389(10074):1134-1150
pubmed: 27865536
Curr Top Microbiol Immunol. 2014;381:279-326
pubmed: 24831346
Immunology. 2005 Sep;116(1):1-12
pubmed: 16108812
Biochem Biophys Res Commun. 2017 Nov 4;493(1):1-8
pubmed: 28859982
Nature. 2013 Feb 14;494(7436):261-5
pubmed: 23334414
Ann Afr Med. 2019 Jul-Sep;18(3):121-126
pubmed: 31417011
Sci Signal. 2016 May 03;9(426):ra46
pubmed: 27141930
Nat Immunol. 2016 Jun 21;17(7):758-64
pubmed: 27328005
Nat Immunol. 2016 Aug;17(8):997-1004
pubmed: 27322655
Nat Med. 2014 Jan;20(1):54-61
pubmed: 24336249
Immunity. 2013 Apr 18;38(4):769-81
pubmed: 23453631
J Mol Med (Berl). 2016 May;94(5):535-43
pubmed: 26922618
Nat Immunol. 2017 Sep;18(9):995-1003
pubmed: 28759002
Immunity. 2017 Jan 17;46(1):148-161
pubmed: 27986455
Nat Rev Immunol. 2017 Nov;17(11):665-678
pubmed: 28804130
Proc Natl Acad Sci U S A. 2018 Feb 13;115(7):1588-1592
pubmed: 29429965
Science. 2018 Mar 23;359(6382):1350-1355
pubmed: 29567705
Int J Cancer. 2014 Apr 1;134(7):1669-82
pubmed: 24105680
Nat Immunol. 2017 Sep;18(9):1004-1015
pubmed: 28759001
Nat Rev Cancer. 2016 Jan;16(1):7-19
pubmed: 26694935
Nature. 2015 Jan 15;517(7534):293-301
pubmed: 25592534
Immunity. 1997 Oct;7(4):493-504
pubmed: 9354470
J Immunol. 2018 Jun 1;200(11):3762-3768
pubmed: 29661825
Nat Immunol. 2016 Jun;17(6):636-45
pubmed: 27111145
Eur J Immunol. 1975 Feb;5(2):112-7
pubmed: 1234049
Int J Mol Sci. 2019 Jun 11;20(11):
pubmed: 31212601
BMC Cancer. 2018 Mar 27;18(1):341
pubmed: 29587679